ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX) announced today the underwriters of its previously-announced underwritten public offering have exercised, in full, their option to purchase from Inhibitex an additional 1,719,512 shares of the Company’s common stock to cover over-allotments. The net proceeds to Inhibitex from the sale of these additional shares at a price of $4.10 per share, after deducting the underwriting discount, are expected to be approximately $6.6 million. This brings the total expected net proceeds of the offering to Inhibitex, after deducting the underwriting discount and estimated offering expenses, to approximately $50.6 million. The offering closed today, April 12, 2011.
